The biotech segment is a relatively new sector that combines the fields of biology and technology. It integrates natural sciences from biology and engineering aspects from technology to develop products with meaningful applications in areas like medicine, agriculture, therapeutics, and more. It possesses an astonishing Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, companies in the biotech sector carry an immense risk because their performances are largely dependent on drug approvals, which are difficult to predict. A successful drug approval during a health crisis has the potential to give returns in multiples whereas a failure could cause sharp declines in stock prices. This is especially true and dangerous when investors hold high expectations for drug approvals and it fails. Due to this reason, investors should be cautious and understand the risks of investing in biotech companies. Below are three biotech stocks to sell in July before they crash and investors lose their money. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cassava Sciences (SAVA) Cassava Sciences (SAVA) company logo icon on website Source: Postmodern Studio / Shutterstock.com Cassava Sciences (NASDAQ:SAVA) is a biotech company that has made its name to the public from its Alzheimer’s treatment named Simufilam. While the company is known for Simulfiam, the success of this new developing treatment is highly questionable and the future of the company highly depends on the outcome of the supposedly developing Alzheimer’s treatment. In the first quarter of 2024, Cassava Science was able to turn things around and reach $25 million in net income as opposed to a $24.3 million net loss. However, Cassava Sciences is still facing larger challenges that could cause significant damage in the future. The Texas-based biotech firm has yet to resolve the ongoing accusations of data manipulation in the Simufilam trial. Right now, Cassava Sciences has simply too many red flags for investors to be confident about stock recovery. Before it is too late, investors stop taking chances with Cassava Sciences and other biotech stocks to sell. Moderna (MRNA) red text reads "moderna" on a light blue background. there is a bottle of liquid vaccine next to a medical needle Source: diy13 / Shutterstock Moderna (NASDAQ:MRNA) was one of the main vaccine producers for the COVID-19 pandemic. From the global outbreak, Moderna naturally made its name known to the public, and its stock price went through the roof and its peak price almost reached $450.00. However, Moderna has been very disappointing since the COVID-19 pandemic from investors’ point of view. It has not established any significant instruments that could contribute to stable long-term growth. As of writing, a share of Moderna stock goes for $117.07. In the recent outbreak of bird flu, Moderna received $176 million from the U.S. government to develop an mRNA bird flu vaccine, which allowed its stock to bounce back. However, this is only a short-term surge and is not indicative of Moderna’s long-term destiny. If anything, it demonstrates to investors that Moderna is overly reliant on health crises and at its fairly overpriced value, investors should treat Moderna among biotech stocks to sell. Ginkgo Bioworks (DNA) Person holding mobile phone with logo of American biotechnology company Ginkgo Bioworks Inc. on screen in front of web page. Focus on phone display. Unmodified photo. DNA stock Source: T. Schneider / Shutterstock.com Ginkgo Bioworks (NYSE:DNA) is an American biotech company based in Boston, Massachusetts. The company was founded by five scientists from MIT back in 2008. In the beginning, it has made promising applications in the biotech field where it developed cell programming solutions. Its technology is mainly used to help produce innovative therapeutics and food ingredients in the agricultural field as well as contribute to research in the field of drug therapy. However, the company has not been performing well financially in recent years. Compared to peak revenue of $477.7 million two years ago, its revenue almost halved to a mere $208 million in 2024. Currently, its stock price is well below the $1 mark. Furthermore, Ginkgo Bioworks is getting heavily targeted by short sellers. They are questioning the company’s unstable revenue sources, corporate strategy, and management. For investors, the smartest decision to make with Ginkgo Bioworks is to leave as soon as they can without giving it a second thought. On the date of publication, Andy Kim did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article. Andy is a self-taught investor who is interested in ESG and socially responsible investing. He has managed the portfolio of a small investment fund and started his own research firm. Through his freelance writing on InvestorPlace, he hopes to find and share promising investments in companies with the goal of bettering the world. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future” The post 3 Biotech Stocks to Sell in July Before They Crash & Burn appeared first on InvestorPlace.
3 Biotech Stocks to Sell in July Before They Crash & Burn
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...